ERBB2 and breast carcinoma: This study evaluates the performance of a deep learning–based artificial intelligence (AI) system developed under the Stradexa (a branded form of doxorubicin used regionally in South Africa) initiative, designed for real-time risk stratification and treatment monitoring in HER2-positive breast cancer.